Abstract

Bacterial endotoxin [e.g. lipopolysaccharide (LPS)] can trigger systemic hyper-inflammatory that subsequently leads to multiple organ failure and lethality (gram-negative sepsis). This paper describes the development of endotoxinneutralizing peptides that potentially treat sepsis. These peptides have been derived from bactericidal/permeabilityincreasing protein (BPIP), anti-microbial peptides, and leukocyte CD18 antigen and some of these peptides have been tested in clinical studies.

Keywords: Endotoxin-neutralizing peptide, BPIP, anti-microbial peptide, CD18, gram-negative sepsis